Streamline Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.30 M
as on 18-07-2024
- Revenue 52.35%
(FY 2022)
- Profit 102.08%
(FY 2022)
- Ebitda -3.02%
(FY 2022)
- Net Worth 0.73%
(FY 2022)
- Total Assets 1.65%
(FY 2022)
About Streamline Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.30 M.
Ajay Gupta and Munish Kumar serve as directors at the Company.
- CIN/LLPIN
U24232PB2006PTC030660
- Company No.
030660
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Jagraon, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Streamline Pharma Private Limited offer?
Streamline Pharma Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Herbal Capsules, Nutraceuticals & Dietary Supplements, Dietary Supplements, Ayurvedic Powder and Medicinal Herbs, Herbs,Sticks and Roots, Ayurvedic Medicine, Ayurvedic Herbal Syrups & Tonics, Digestive System Drugs & Medicines, Gastrointestinal Drugs.
Who are the key members and board of directors at Streamline Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Munish Kumar  | Director | 19-Oct-2006 | Current |
| Ajay Gupta | Director | 19-Oct-2006 | Current |
Financial Performance of Streamline Pharma.
Streamline Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 52.35% increase. The company also saw a substantial improvement in profitability, with a 102.08% increase in profit. The company's net worth moved up by a moderate rise of 0.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Streamline Pharma?
In 2022, Streamline Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 Jan 2022 | ₹1.30 M | Open |
How Many Employees Work at Streamline Pharma?
Unlock and access historical data on people associated with Streamline Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Streamline Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Streamline Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
